Navigation Links
Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting
Date:5/21/2009

nited States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer.(i) In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The Dimebon program also includes additional trials planned to begin this year in Alzheimer's disease, as well as further development of Dimebon in patients with Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.

(i) American Cancer Society

    Contacts:
    Medivation, Inc.                                WeissComm Partners
    Patrick Machado,
'/>"/>
SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
2. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
3. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
4. Medivation Announces Participation in Upcoming Conferences
5. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
8. Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
9. Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
10. Medivation Reports First Quarter 2009 Financial Results and Provides Corporate Update
11. Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... Hills, California (PRWEB) December 25, 2014 ... her home in Woodland Hills, California after an 8 ... passed away on Christmas Eve evening in her home ... with aggressive metastatic breast cancer. , ... for over forty years, she pioneered and championed many ...
(Date:12/25/2014)... 2014 Recently, LunaDress.co.uk has updated its blog to ... accessories. Now, all of the models at LunaDress.co.uk come with big ... lifts the wedding veil can turn out to be a most ... wedding veil can always bring surprise to a wedding. On the ... to choose veils for a big day . , Going ...
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- The risk of burns ... so you need to be extra cautious, an expert ... see a significant increase in patients coming in with ... Suffolk County Volunteer Firefighters Burn Center of Stony Brook ... be full of joy, but if not careful, could ...
(Date:12/25/2014)... Dec. 24, 2014 (HealthDay News) -- Among early stage ... less than half of one percent will eventually develop ... analysis reveals. The finding comes from a review ... 1998 and 2007, and it suggests that the risk ... what experts had previously thought. "The frequency of ...
(Date:12/25/2014)... December 25, 2014 AngelWeddingDress.com tries its ... the online realm. Today, the business has introduced its ... site-wide prom dress promotion. , The new prom outfits ... and every dress lover. They are specially designed for ... prom dresses should visit its website before Jan. ...
Breaking Medicine News(10 mins):Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... Denying Right, to Fly; Case Could Set Precedent for Airline Travel Rights ... ... Oct. 5 A 26-year-old disabled man,who was denied access to a ... Andy Gates is affected by dystonia, an obscure neuromuscular movement,disorder that causes ...
... Oct. 5 /PRNewswire-FirstCall/ - MaxLife Fund Corp.,(OTC:MXFD), announced today ... Jaclin, LLP to review the company options to be ... that listing on the NASDAQ Capital Market will,provide greater ... of information to our shareholders and potential investors. ...
... NanoBio(R) Corporation, a,biopharmaceutical company developing and commercializing novel ... has been honored as a,recipient of the 2007 ... honor Michigan companies whose innovative,products, processes or business ... bestowed by Michigan Business Review, and its,recipients and ...
... weight loss is good for the heart, researchers say , , ... are equally heart-healthy, according to a study ranking eight popular ... and vegetables scored better than those with a heavy protein ... with the most potential to prevent heart disease risk factors. ...
... LAKE, N.J., Oct. 5 Barr,Pharmaceuticals, Inc. (NYSE: ... Conference Call at 8:30 AM Eastern time on Thursday, ... of calendar 2007, ended,September 30, 2007. The number to ... (651) 224-7558 Internationally. A replay of the,conference call will ...
... Oct. 5 Riverside Partners, based in ... has partnered with management to acquire,GEMCITY Engineering ... GEM is a contract and specialized equipment ... healthcare, semiconductor, and,industrial machinery markets. The Company ...
Cached Medicine News:Health News:Major US Airline Discriminates Against Disabled Passenger, Lawsuit Charges 2Health News:NanoBio Wins 2007 Michigan Innovation Award 2Health News:Study Rates Heart Health of Popular Diet Plans 2Health News:Study Rates Heart Health of Popular Diet Plans 3Health News:Study Rates Heart Health of Popular Diet Plans 4Health News:Barr Will Host Calendar 2007 Third Quarter Earnings Conference Call on November 8, 2007 2Health News:Barr Will Host Calendar 2007 Third Quarter Earnings Conference Call on November 8, 2007 3Health News:Riverside Partners Teams with Management to Acquire GEMCITY Engineering & Manufacturing 2
(Date:12/24/2014)... -- Lockton Dunning Benefits, the Dallas ... of Vice President Kim Foerster on ... team, Excelsior Solutions. Foerster brings ... position.  Most recently, she worked as the Director ... where she has held various managerial positions since ...
(Date:12/24/2014)... BARBARA, Calif. , Dec. 23, 2014 In ... Junior Doctors, Association of Sierra Leone , ... Sierra Leone for the treatment of local health ... While a new dedicated Ebola care center was constructed ... virus, the facility is not available for local Sierra Leonean ...
(Date:12/22/2014)... , Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), ... CytoSorb® blood purification technology to help fight deadly ... 28 countries worldwide, today announced the appointment of ... FACS, as its Senior Vice President of Clinical ... Dr. Di Russo is an accomplished ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... EAST HANOVER, N.J., April 12, 2011 Novartis ... Food and Drug Administration (FDA) Oncologic Drugs Advisory ... for the treatment of patients with advanced neuroendocrine ... recommendation was provided after presentation of data from ...
... The association representing Montana,s providers of home medical ... Congress to repeal the controversial Medicare "competitive" bidding program ... "It is imperative that H.R. 1041 pass if we ... and local businesses in Montana," said Mike Calcaterra, Montana ...
Cached Medicine Technology:Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 3Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 4Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 5Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 6Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 7Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 8Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 9Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 10Montana Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 2Montana Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 3Montana Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 4
... Shuttle Relay Suture Passer allows braided suture ... repair procedures. It may be used ... material and in conjunction with anchors or ... Additionally, the Shuttle Relay can be ...
The 4mm diameter Revo suture anchor is designed primarily for arthroscopic and open rotator cuff repair. Additional applications include other shoulder repair procedures, as well as use in knees and ...
... sutureless fixation device offers superior fixation ... implant firmly reattaches soft tissue to ... CuffTack is indicated for the fixation ... to bone. The implant is composed ...
... use system can be used for open ... pre-packaged on a sterile disposable inserter. The ... and reproducible insertion of the anchor into ... Eyelet Design allows for the two pre-threaded ...
Medicine Products: